Abstract
The advent of newer therapies has significantly improved the outcomes in patients (pts) with refractory multiple myeloma (MM). However, the treatment of elderly pts remains challenging. Selinexor (SEL) is a novel, oral selective inhibitor of nuclear export (SINE) which forces nuclear retention and activation of tumor suppressor proteins. SEL plus low dose dexamethasone (SEL-DEX) induced an overall response rate (ORR) of 26.2% in pts with penta-exposed, triple-class refractory MM. Side effects were generally reversible without evidence of major organ toxicities.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.